Glofitamab
- Generic Name
- Glofitamab
- Brand Names
- Columvi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2229047-91-8
- Unique Ingredient Identifier
- 06P3KLK2J8
- Background
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...
- Indication
Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...
- Associated Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.